The safety of mineralocorticoid receptor antagonists (MRAs) in patients with heart failure.
Identifieur interne : 000135 ( Main/Exploration ); précédent : 000134; suivant : 000136The safety of mineralocorticoid receptor antagonists (MRAs) in patients with heart failure.
Auteurs : Bertram Pitt [États-Unis] ; Patrick Rossignol [France]Source :
- Expert opinion on drug safety [ 1744-764X ] ; 2016.
Abstract
Mineralocorticoid receptor antagonists (MRAs) have been accorded a class 1 indication for patients with chronic heart failure and a reduced left ventricular ejection fraction (HFREF) in both European and American guidelines. Uptake, however, has been less than optimal largely due to concerns about their safety, in particular the risk of hyperkalemia and renal dysfunction.
DOI: 10.1517/14740338.2016.1163335
PubMed: 26958701
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000013
- to stream PubMed, to step Curation: 000013
- to stream PubMed, to step Checkpoint: 000002
- to stream Ncbi, to step Merge: 000231
- to stream Ncbi, to step Curation: 000223
- to stream Ncbi, to step Checkpoint: 000223
- to stream Main, to step Merge: 000121
- to stream Main, to step Curation: 000135
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The safety of mineralocorticoid receptor antagonists (MRAs) in patients with heart failure.</title><author><name sortKey="Pitt, Bertram" sort="Pitt, Bertram" uniqKey="Pitt B" first="Bertram" last="Pitt">Bertram Pitt</name><affiliation wicri:level="1"><nlm:affiliation>a School of Medicine , University of Michigan , Ann Arbor , MI , USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>a School of Medicine , University of Michigan , Ann Arbor , MI </wicri:regionArea><wicri:noRegion>MI </wicri:noRegion></affiliation></author><author><name sortKey="Rossignol, Patrick" sort="Rossignol, Patrick" uniqKey="Rossignol P" first="Patrick" last="Rossignol">Patrick Rossignol</name><affiliation wicri:level="4"><nlm:affiliation>b Inserm, Centre d'Investigations Cliniques- Plurithématique 14-33, Inserm U1116, CHU Nancy , Université de Lorraine, Association Lorraine de Traitement de l'Insuffisance Rénale, and F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists) , Nancy , France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>b Inserm, Centre d'Investigations Cliniques- Plurithématique 14-33, Inserm U1116, CHU Nancy , Université de Lorraine, Association Lorraine de Traitement de l'Insuffisance Rénale, and F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists) , Nancy </wicri:regionArea><wicri:noRegion>Nancy </wicri:noRegion><orgName type="university">Université de Lorraine</orgName><placeName><settlement type="city">Nancy</settlement><settlement type="city">Metz</settlement><region type="region" nuts="2">Grand Est</region><region type="old region" nuts="2">Lorraine (région)</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:26958701</idno><idno type="pmid">26958701</idno><idno type="doi">10.1517/14740338.2016.1163335</idno><idno type="wicri:Area/PubMed/Corpus">000013</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000013</idno><idno type="wicri:Area/PubMed/Curation">000013</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000013</idno><idno type="wicri:Area/PubMed/Checkpoint">000002</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000002</idno><idno type="wicri:Area/Ncbi/Merge">000231</idno><idno type="wicri:Area/Ncbi/Curation">000223</idno><idno type="wicri:Area/Ncbi/Checkpoint">000223</idno><idno type="wicri:Area/Main/Merge">000121</idno><idno type="wicri:Area/Main/Curation">000135</idno><idno type="wicri:Area/Main/Exploration">000135</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The safety of mineralocorticoid receptor antagonists (MRAs) in patients with heart failure.</title><author><name sortKey="Pitt, Bertram" sort="Pitt, Bertram" uniqKey="Pitt B" first="Bertram" last="Pitt">Bertram Pitt</name><affiliation wicri:level="1"><nlm:affiliation>a School of Medicine , University of Michigan , Ann Arbor , MI , USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>a School of Medicine , University of Michigan , Ann Arbor , MI </wicri:regionArea><wicri:noRegion>MI </wicri:noRegion></affiliation></author><author><name sortKey="Rossignol, Patrick" sort="Rossignol, Patrick" uniqKey="Rossignol P" first="Patrick" last="Rossignol">Patrick Rossignol</name><affiliation wicri:level="4"><nlm:affiliation>b Inserm, Centre d'Investigations Cliniques- Plurithématique 14-33, Inserm U1116, CHU Nancy , Université de Lorraine, Association Lorraine de Traitement de l'Insuffisance Rénale, and F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists) , Nancy , France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>b Inserm, Centre d'Investigations Cliniques- Plurithématique 14-33, Inserm U1116, CHU Nancy , Université de Lorraine, Association Lorraine de Traitement de l'Insuffisance Rénale, and F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists) , Nancy </wicri:regionArea><wicri:noRegion>Nancy </wicri:noRegion><orgName type="university">Université de Lorraine</orgName><placeName><settlement type="city">Nancy</settlement><settlement type="city">Metz</settlement><region type="region" nuts="2">Grand Est</region><region type="old region" nuts="2">Lorraine (région)</region></placeName></affiliation></author></analytic><series><title level="j">Expert opinion on drug safety</title><idno type="eISSN">1744-764X</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Mineralocorticoid receptor antagonists (MRAs) have been accorded a class 1 indication for patients with chronic heart failure and a reduced left ventricular ejection fraction (HFREF) in both European and American guidelines. Uptake, however, has been less than optimal largely due to concerns about their safety, in particular the risk of hyperkalemia and renal dysfunction.</div></front></TEI><affiliations><list><country><li>France</li><li>États-Unis</li></country><region><li>Grand Est</li><li>Lorraine (région)</li></region><settlement><li>Metz</li><li>Nancy</li></settlement><orgName><li>Université de Lorraine</li></orgName></list><tree><country name="États-Unis"><noRegion><name sortKey="Pitt, Bertram" sort="Pitt, Bertram" uniqKey="Pitt B" first="Bertram" last="Pitt">Bertram Pitt</name></noRegion></country><country name="France"><region name="Grand Est"><name sortKey="Rossignol, Patrick" sort="Rossignol, Patrick" uniqKey="Rossignol P" first="Patrick" last="Rossignol">Patrick Rossignol</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Lorraine/explor/InforLorV4/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000135 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000135 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Lorraine
|area= InforLorV4
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:26958701
|texte= The safety of mineralocorticoid receptor antagonists (MRAs) in patients with heart failure.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:26958701" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a InforLorV4
| This area was generated with Dilib version V0.6.33. |  |